MedTrace Logo

A Study Of The Efficacy And Safety Of Sunitinib In Patients With Advanced Well-Differentiated Pancreatic Neuroendocrine Tumors

NCT01525550 · Status: COMPLETED · Phase: PHASE4 · Type: INTERVENTIONAL · Enrollment: 106

Last updated 2019-07-30

Study results available
· View outcomes & findings →

Summary

The purpose of this study is to confirm the safety and efficacy of sunitinib in subjects with unresectable pancreatic neuroendocrine tumors.

Conditions

  • Well-differentiated Pancreatic Neuroendocrine Tumor

Interventions

DRUG

sunitinib

Sunitinib capsules will be given orally at continuous daily dosing with a starting dose of 37.5 mg. One cycle is equal to 28 days.

Sponsors & Collaborators

Principal Investigators

  • Pfizer CT.gov Call Center · Pfizer

Study Design

Purpose
OTHER
Masking
NONE

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2012-06-06
Primary Completion
2016-03-19
Completion
2018-07-26

Countries

  • United States
  • Australia
  • Belgium
  • China
  • Czechia
  • France
  • Hungary
  • India
  • Italy
  • Japan
  • Norway
  • Romania
  • Slovakia
  • South Africa
  • Spain

Study Locations

More Related Trials

Entities

Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01525550 on ClinicalTrials.gov